ATE132909T1 - Vefahren zur diagnose von störungen der blutgerinnung - Google Patents

Vefahren zur diagnose von störungen der blutgerinnung

Info

Publication number
ATE132909T1
ATE132909T1 AT92913443T AT92913443T ATE132909T1 AT E132909 T1 ATE132909 T1 AT E132909T1 AT 92913443 T AT92913443 T AT 92913443T AT 92913443 T AT92913443 T AT 92913443T AT E132909 T1 ATE132909 T1 AT E132909T1
Authority
AT
Austria
Prior art keywords
conversion
sample
rate
blood clotting
clotting disorders
Prior art date
Application number
AT92913443T
Other languages
English (en)
Inventor
Bjoern Dahlbaeck
Original Assignee
Bjoern Dahlbaeck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE132909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9103332A external-priority patent/SE470274B/sv
Application filed by Bjoern Dahlbaeck filed Critical Bjoern Dahlbaeck
Application granted granted Critical
Publication of ATE132909T1 publication Critical patent/ATE132909T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92913443T 1991-11-13 1992-05-13 Vefahren zur diagnose von störungen der blutgerinnung ATE132909T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103332A SE470274B (sv) 1991-11-13 1991-11-13 Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar
US81130391A 1991-12-20 1991-12-20

Publications (1)

Publication Number Publication Date
ATE132909T1 true ATE132909T1 (de) 1996-01-15

Family

ID=26661244

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92913443T ATE132909T1 (de) 1991-11-13 1992-05-13 Vefahren zur diagnose von störungen der blutgerinnung

Country Status (10)

Country Link
EP (1) EP0608235B2 (de)
JP (1) JP2562000B2 (de)
AT (1) ATE132909T1 (de)
CA (1) CA2119761C (de)
DE (2) DE608235T1 (de)
DK (1) DK0608235T4 (de)
ES (1) ES2081618T5 (de)
GR (1) GR3018646T3 (de)
HK (1) HK31697A (de)
WO (1) WO1993010261A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
HUT72191A (en) * 1993-01-29 1996-03-28 Dahlbaeck Novel anticoagulant cofactor activity
US5472852A (en) * 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients
ATE213023T1 (de) * 1993-12-03 2002-02-15 Baxter Ag Test zur bestimmung der empfindlichkeit gegenüber aktiviertem protein c
KR100384251B1 (ko) * 1994-02-14 2003-09-19 리엑스 유니버시타이트 라이덴 활성화된단백질c에대한약한항응고반응및/또는혈전증과관련된유전자결함의존재를검색하는방법
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
AUPM731394A0 (en) * 1994-08-05 1994-09-01 Life Therapeutics Limited Improved activated protein c resistance test
EP0711838B2 (de) † 1994-11-10 2007-06-20 Dade Behring Marburg GmbH Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6867045B1 (en) 1994-11-14 2005-03-15 The Scripps Research Institute Method for diagnosis of thrombotic disorders
ATE200710T1 (de) † 1994-12-23 2001-05-15 Diagnostic Reagents Ltd Verfahren zur diagnose von blutgerinnungsstörungen
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
US5780255A (en) * 1995-06-09 1998-07-14 Instrumentation Laboratory, S.P.A. Protein C pathway screening test
AT403289B (de) * 1996-01-30 1997-12-29 Immuno Ag Verfahren zur herstellung eines standardisierten plasmapools für diagnostische zwecke
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
FR2764389B1 (fr) 1997-06-06 1999-08-06 Stago Diagnostica Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
DE19724239A1 (de) * 1997-06-09 1998-12-10 Max Planck Gesellschaft Dysprothrombinämie
US6743596B1 (en) 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
RU2518247C2 (ru) * 2011-07-26 2014-06-10 Общество с ограниченной ответственностью "ГемаКор Лабс" (ООО "ГемаКор Лабс") Способ определения пространственно-временного распределения активности протеолитического фермента в гетерогенной системе, устройство для реализации указанного способа и способ диагностики нарушений системы гемостаза по изменению пространственно-временного распределения активности протеолитического фермента в гетерогенной системе
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
RU2752776C1 (ru) * 2020-12-16 2021-08-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения длительности тромбопрофилактики низкомолекулярным гепарином после абдоминального родоразрешения у носителей мутации Лейден, генотип F5 G1691A

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051357A (en) * 1989-07-14 1991-09-24 Board Of Trustees Operating Michigan State University Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
WO1991001383A1 (en) * 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
SE464135B (sv) † 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5169786A (en) * 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
EP0711838B2 (de) † 1994-11-10 2007-06-20 Dade Behring Marburg GmbH Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C
US5705395A (en) † 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders

Also Published As

Publication number Publication date
EP0608235A1 (de) 1994-08-03
HK31697A (en) 1997-03-21
DE69207607T2 (de) 1996-06-20
DE69207607D1 (de) 1996-02-22
ES2081618T5 (es) 2005-09-01
AU666484B2 (en) 1996-02-15
DK0608235T4 (da) 2005-05-30
DE69207607T3 (de) 2006-07-06
CA2119761C (en) 1997-12-16
AU2198092A (en) 1993-06-15
DK0608235T3 (da) 1996-02-12
EP0608235B1 (de) 1996-01-10
GR3018646T3 (en) 1996-04-30
ES2081618T3 (es) 1996-03-16
CA2119761A1 (en) 1993-05-27
DE608235T1 (de) 1994-12-22
JPH07501217A (ja) 1995-02-09
JP2562000B2 (ja) 1996-12-11
WO1993010261A1 (en) 1993-05-27
EP0608235B2 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
ATE132909T1 (de) Vefahren zur diagnose von störungen der blutgerinnung
WO1997012992A3 (en) Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
CA2282746A1 (en) Prediction of coronary artery disease
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DK0994963T4 (da) Noninvasiv prænatal diagnose
EP0391714A3 (de) Verfahren zum Nachweis der Alzheimer-Krankheit: Untersuchung des nicht-neuralen Gewebes
NO972006D0 (no) Ny metode for diagnose av sykdommer
ATE63168T1 (de) Kontroll- bzw. eichserum fuer die lipiddiagnostik.
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
PT948604E (pt) Produtos e metodos relacionados com pyk2
DE3783966T2 (de) Reagens zur pruefung von periodentalen erkrankungen.
ATE272214T1 (de) Verfahren zur diagnose von sepsis unter bestimmung von s100b
ATE189742T1 (de) Test zur diagnose von demenz
WO2002033420A3 (en) A urine test for the diagnosis of prion diseases
DE69734890D1 (de) Rdgb-proteine
CA2332310A1 (en) Antibody against protein tyrosine phosphatase intracellular domains
ES2099876T3 (es) Procedimiento para la determinacion de anticuerpos de lupus anticoagulante que provocan trombosis.
RU2141667C1 (ru) Способ диагностики эрозивного гастродуоденита и язвенной болезни у детей
SU1714510A1 (ru) Способ определени гормональной зависимости при аутоиммунных заболевани х
DE69918128D1 (de) Mutierte gewebefaktor-inhibitor (tfpi), dna sequenz davon und verwendung zur erkennung von thrombotischen erkrankungen
Komiyama et al. Activated coagulation factors in various thrombotic diseases
AU2713288A (en) Human-type serum obtained from fractions resulting from the fractionation of human blood or serum, process for its preparation and laboratory reaction containing said serum
WO1999064584A3 (de) Protein zur regulation von apoptose
RU93013396A (ru) Способ определения мембранной активации свертывания плазмы крови

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee